Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | CDC25C | P30307 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 9/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL4251892 | 1.00 | CDC25A (0.53) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1918963 | 0.89 | CDC25A (0.65) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1917038 | 0.89 | CDC25A (0.65) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1917797 | 0.80 | CDC25A (0.61) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1919704 | 0.76 | CDC25A (0.61) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1917181 | 0.76 | MALT1 (0.51) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1916884 | 0.74 | S100A4 (0.45) | CDC25ACDC25BCDC25CCDK4MALT1 | |
| SCHEMBL1918600 | 0.74 | S100A4 (0.45) | CDC25ACDC25BCDC25CMALT1BLM | |
| SCHEMBL1917262 | 0.73 | S100A4 (0.45) | CDC25ACDC25BCDC25CMALT1BLM | |
| SCHEMBL1917647 | 0.73 | CDC25A (0.66) | CDC25ACDC25BCDC25CCDK4MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | CDC25A 1/4885CDC25B 3/4885CDC25C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.